Predicting risk of breast cancer recurrence using gene-expression profiling - PubMed (original) (raw)
Review
Predicting risk of breast cancer recurrence using gene-expression profiling
Michail Ignatiadis et al. Pharmacogenomics. 2007 Jan.
Abstract
The molecular profiling of breast tumors using the powerful microarray technology has uncovered the molecular heterogeneity of breast tumors and has offered novel insight into breast tumorigenesis. The estrogen receptor (ER) has been shown to be the most important discriminator dichotomizing breast cancer into two main subsets. At the same time, proliferation, as captured by the recently developed Genomic Grade Index (GGI) has been found to be the most important prognostic factor in breast cancer, far beyond ER status. Interestingly, this index encompasses a significant portion of the predictive power of many published prognostic signatures. The challenge now is to integrate all the prognostic gene signatures available to date towards a comprehensive genomic fingerprint of the primary tumor. In the future, we should be able to offer individualized treatment to our patients based on a clinical decision-making algorithm that takes into account the clinicopathological parameters, the genomic profile of the primary tumor, the presence of micrometastatic cells and pharmacogenetic data for drug response.
Similar articles
- Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ. Kreike B, et al. Clin Cancer Res. 2006 Oct 1;12(19):5705-12. doi: 10.1158/1078-0432.CCR-06-0805. Clin Cancer Res. 2006. PMID: 17020974 - Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C. Bedard PL, et al. Endocr Relat Cancer. 2011 Nov 14;18(6):721-30. doi: 10.1530/ERC-11-0180. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21984694 - Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial. - Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS. Ross JS. Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review. - Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F, Reis-Filho JS. Correa Geyer F, et al. Int J Surg Pathol. 2009 Aug;17(4):285-302. doi: 10.1177/1066896908328577. Epub 2008 Dec 22. Int J Surg Pathol. 2009. PMID: 19103611 Review.
Cited by
- Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
Mouttet D, Laé M, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Vincent-Salomon A, Rouzier R, Sigal-Zafrani B, Sastre-Garau X, Reyal F. Mouttet D, et al. PLoS One. 2016 Feb 1;11(2):e0146474. doi: 10.1371/journal.pone.0146474. eCollection 2016. PLoS One. 2016. PMID: 26829108 Free PMC article. - Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Singh PK, et al. Oncotarget. 2014 Feb 15;5(3):824-40. doi: 10.18632/oncotarget.1776. Oncotarget. 2014. PMID: 24583788 Free PMC article. - Tailoring to RB: tumour suppressor status and therapeutic response.
Knudsen ES, Knudsen KE. Knudsen ES, et al. Nat Rev Cancer. 2008 Sep;8(9):714-24. doi: 10.1038/nrc2401. Nat Rev Cancer. 2008. PMID: 19143056 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical